Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  Clinigen Group PLC    CLIN   GB00B89J2419

CLINIGEN GROUP PLC

(CLIN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Clinigen : Accord Healthcare extend exclusive European clinical trial supply agreement

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/12/2019 | 03:51am EDT

Clinigen Group plc (Clinigen), the global pharmaceutical and services company, announces that its Clinical Trial Service (CTS) business has extended its exclusive European clinical trial supply agreement with Accord Healthcare (Accord). Clinigen is also offering pharma companies an on demand service to Accords products, a first for the industry.

Clinigen and Accord have been partnered since 2012 to deliver oncology Injectable Products, including carboplatin, cisplatin and paclitaxel, into clinical trials. The extended agreement now covers Accords European Solid Dose Products, including those in the central nervous system, autoimmune, diabetes and anti-viral therapy areas.

The CTS team is the sole point of contact for all clinical trial supply enquiries, ensuring an effective and secure supply chain in the distribution of Accords European product portfolio to pharmaceutical manufacturers, contract research organizations (CROs), clinical trial contract packagers and other specialist service providers. The drugs are supplied for use as comparator, co-therapy, rescue and adjunctive drugs in clinical trials.

The on demand supply service will be available for any Clinigen client running clinical trials. They will be offered instant access to key products from Accord`s generic oncology Injectable Product portfolio. Products will be held in large batch sizes on consignment ready for instant dispatch to new and existing clinical trials.

This is the first type of dedicated service providing instant access to products solely for clinical trials in the industry and directly tackles the constant timeline and flexibility challenges experienced when running clinical trials.

Shaun Chilton, Group Chief Executive Officer of Clinigen, said:

This extended agreement builds on the strong partnership we have with Accord in providing access to its medicines for use in clinical trials.

The launch of our on demand offering demonstrates the ability we have across the Group and the specialisms we have in the supply and distribution of medicines. These capabilities enable us to provide the best possible service to those running clinical trials.

Phill Semmens, Senior Vice President Commercial, Accord Healthcare, EMENA, said:

We are delighted that the strong collaboration Accord and Clinigen have built over the past six years continues to expand with the agreement to include solid dose oral products.

The scope of this partnership is a first for the industry, allowing us to ensure that our products are available as comparators in a variety of vital clinical trials, helping to further medical knowledge and the identification of new treatment options to improve patient care.

(c) 2019 Gulf Sports Media All rights reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CLINIGEN GROUP PLC
07/01CLINIGEN : Jet-lag medication approved by MHRA
AQ
06/26CLINIGEN : MHRA licenses two Melatonin products indicated for short-term jet-lag..
PU
06/24CLINIGEN : broadens partnership with Accord Healthcare to supply and distribute ..
PU
05/16CUMBERLAND PHARMACEUTICALS : Clinigen to assume control of us commercial rights ..
AQ
05/01CLINIGEN : Appoints James Meyer as General Manager of Commercial Medicines in th..
BU
04/02CLINIGEN : completes acquisition of US rights to Proleukin
PU
03/27CLINIGEN : S foscavir gains approval for hhv-6 encephalitis in japan
AQ
03/26CLINIGEN : Foscavir® gains approval for HHV-6 encephalitis in Japan
PU
03/21CLINIGEN GROUP PLC : Ex-dividend day for interim dividend
FA
02/27CLINIGEN : Half Year Results for the Six Months Ended 31 December 2018
PU
More news
Financials (GBP)
Sales 2019 452 M
EBIT 2019 96,3 M
Net income 2019 41,8 M
Debt 2019 251 M
Yield 2019 0,64%
P/E ratio 2019 30,7x
P/E ratio 2020 16,2x
EV / Sales2019 3,47x
EV / Sales2020 2,94x
Capitalization 1 315 M
Chart CLINIGEN GROUP PLC
Duration : Period :
Clinigen Group PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CLINIGEN GROUP PLC
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Average target price 13,4  GBP
Last Close Price 9,93  GBP
Spread / Highest target 65,2%
Spread / Average Target 35,1%
Spread / Lowest Target 10,8%
EPS Revisions
Managers
NameTitle
Shaun Edward Chilton Chief Executive Officer & Executive Director
Peter Vance Allen Independent Non-Executive Chairman
Martin Abell Chief Financial Officer & Executive Director
Ivo Timmermans Chief Medical Officer
John Hartup Senior Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
CLINIGEN GROUP PLC30.50%1 629
GILEAD SCIENCES5.93%84 164
VERTEX PHARMACEUTICALS6.08%45 080
REGENERON PHARMACEUTICALS-21.67%31 857
SAREPTA THERAPEUTICS INC43.04%11 437
GENMAB9.70%11 148